N/A
Completed N=1,390
Real-world Study of Dedifferentiated Liposarcoma Patients in China
Dedifferentiated Liposarcoma
Source: ClinicalTrials.gov NCT06115681 ↗
Enrolled (actual)
1,390
Serious AEs
—
Results posted
Jul 2025
Primary outcomePrimary: Cohort 1: Overall Survival — 13.4; 11.9; 8.1 months
Summary
This study will characterize patients with dedifferentiated liposarcoma (DDLPS) in China, including an understanding of demographic, and clinical characteristics as well as treatment patterns and clinical outcomes associated with the current real-world treatment.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Cohort 1: Overall Survival |
13.4; 11.9; 8.1 | — |
| SECONDARY Cohort 1, Cohort 2: Survival After Initial Diagnosis |
30.3; 38.4 | — |
| SECONDARY Cohort 1, Cohort 2: Total Number of Treatment Lines |
1.0; 0.0 | — |
| SECONDARY Cohort 1, Cohort 2: First Line (1L) of Therapy by Treatment Type |
119; 12; 85; 12; 15; 1 | — |
| SECONDARY Cohort 1, Cohort 2: Second Line (2L) of Therapy by Treatment Type |
37; 4; 22; 2; 13; 1 | — |
| SECONDARY Cohort 1, Cohort 2: Third Line (3L) of Therapy by Treatment Type |
16; 1; 11; 1; 5; 0 | — |
| SECONDARY Cohort 1, Cohort 2: Number of Patients With Treatments Classified as Concurrent Steroid Therapy |
1; 1 | — |
| SECONDARY Cohort 1, Cohort 2: Number of Patients With Treatments Classified as Concurrent Immunosuppressant Therapy |
32; 2 | — |
| SECONDARY Cohort 1, Cohort 2: Number of Patients With Treatments Classified as Hormone Replacement Therapy |
10; 0 | — |
Eligibility Criteria
Inclusion criteria
- Patient has two or more documented clinical visits in the National Anti-Tumor Drug Surveillance System (NATDSS) network on or after January 1, 2013.
- Patient has a confirmed diagnosis of dedifferentiated liposarcoma (DDLPS) during his/her lifetime.
- At least 18 years old at the date of initial diagnosis.
No exclusion criteria are applied.
Data sourced from ClinicalTrials.gov (NCT06115681). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.